| Seres Sets Sights on FDA After C. Diff Microbiome Therapy Scores in Phase 3 | Frank Vinluan | 08/10/20 | Boston |
| AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact | Frank Vinluan | 08/07/20 | Boston |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds | Frank Vinluan | 08/06/20 | San Francisco |
| GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology | Frank Vinluan | 08/05/20 | Boston |
| Black Diamond Makes Fang Ni’s Chief Business Officer Job Permanent | Sarah de Crescenzo | 08/04/20 | Boston |
| AbbVie Walks From Voyager R&D Pact Spanning Alzheimer’s, Parkinson’s | Frank Vinluan | 08/04/20 | Boston |
| Bluebird’s Susanna High Jumps to Dyne for Chief Operating Officer Role | Frank Vinluan | 08/03/20 | Boston |
| Kymera Therapeutics Unveils IPO Pitch for Protein Degradation | Frank Vinluan | 07/31/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients | Frank Vinluan | 07/30/20 | Boston |
| Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug | Frank Vinluan | 07/29/20 | Europe |
| Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology | Frank Vinluan | 07/29/20 | Boston |
| Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test | Sarah de Crescenzo | 07/29/20 | National |
| Pfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test | Frank Vinluan | 07/28/20 | New York |
| AstraZeneca to Pay $1B to Team Up With Daiichi Sankyo Again in Cancer | Frank Vinluan | 07/27/20 | Europe |
| Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More | Sarah de Crescenzo | 07/24/20 | National |
| Scholar Rock’s Alan Buckler Joins Triplet as Chief Scientific Officer | Frank Vinluan | 07/23/20 | Boston |
| FDA Lifts CymaBay Drug Hold, Tests to Resume in Rare Liver Disease PBC | Frank Vinluan | 07/23/20 | San Francisco |
| Vesigen Nabs $28M to Wrap “ARMMS” Around Large Molecule Drug Delivery | Frank Vinluan | 07/22/20 | Boston |
| Freeline Therapeutics and Checkmate Pharma Make Opening IPO Moves | Frank Vinluan | 07/21/20 | Europe |
| Roche, Jnana Enter Drug R&D Alliance Targeting Metabolism’s Gatekeepers | Frank Vinluan | 07/21/20 | Boston |
| Forge Bio’s Combo Model for Gene Therapies Attracts $40M in Funding | Frank Vinluan | 07/21/20 | National |
| Rhythm Pharma Taps Chairman David Meeker as President & CEO | Frank Vinluan | 07/20/20 | Boston |
| GSK Pays CureVac $328M in mRNA Vaccines Pact—Excluding COVID-19 | Frank Vinluan | 07/20/20 | Europe |
| Two Days, Six IPOs, and $1B Raised for Biotech Research & More | Frank Vinluan | 07/17/20 | National |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| GSK Vaccine Vet Pfefer Tapped for Executive Roles at Flagship, Kintai | Frank Vinluan | 07/16/20 | Boston |
| Adimab Spinout Adagio Raises $50M for Coronavirus Antibody R&D | Sarah de Crescenzo | 07/16/20 | Boston |
| Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test | Frank Vinluan | 07/15/20 | Boston |
